Press release
Geographic Atrophy Therapeutics Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight
DelveInsight's "Geographic Atrophy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Geographic Atrophy, historical and forecasted epidemiology as well as the Geographic Atrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.Discover Key Insights into the Geographic Atrophy Market with DelveInsight's In-Depth Report @ Geographic Atrophy Market Size [https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Geographic Atrophy Market Report
* The total prevalent cases of AMD in the 7MM was nearly 68,347,900 in 2023.
* Among the 7MM, the US accounted for the highest prevalent cases of Geographic Atrophy in 2023 while Japan accounted for the least number of prevalent cases.
* Amongst EU4 and the UK, the highest number of cases comprised from France and Germany, with France having slightly more cases than Germany.
* In 2023, the geographical atrophy accounted for nearly 955,900 cases in EU4 and the UK.
* According to the estimates, in Japan, it is observed that age-specific cases of Geographic Atrophy were most prevalent in the 85+ years age group, accounting for over 40% of total cases in 2023.
* The leading Geographic Atrophy Companies such as Aviceda Therapeutics, Iveric Bio, Alkeus Pharmaceuticals, Allegro Ophthalmics, Stealth BioTherapeutics, Novartis, Perceive Biotherapeutics, Inc., Genentech, Inc., NGM Biopharmaceuticals, Inc, Annexon, Inc., Regenerative Patch Technologies, LLC, Apellis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Astellas Pharma Inc, Gyroscope Therapeutics Limited, and others.
* Promising Geographic Atrophy Pipeline Therapies such as AVD-104, Zimura (avacincaptad pegol), ALK-001, Risuteganib, Elamipretide, PPY988, VOY-101, OpRegen, NGM621, ANX007, CPCB-RPE1, APL-2, IONIS-FB-LRx, ASP7317, GT005, and others.
Stay ahead in the Geographic Atrophy Therapeutics Market with DelveInsight's Strategic Report @ Geographic Atrophy Market Outlook [https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Geographic Atrophy Epidemiology Segmentation in the 7MM
* Total Geographic Atrophy Prevalent Cases
* Geographic Atrophy Late Stage-specific Prevalent Cases
* Total Geographic Atrophy Diagnosed Prevalent Cases
* Geographic Atrophy Age-specific Cases
* Geographic Atrophy Cases by Visual Impairment
Download the report to understand which factors are driving Geographic Atrophy Epidemiology trends @ Geographic Atrophy Prevalence [https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Marketed Geographic Atrophy Drugs
* IZERVAY (avacincaptad pegol): Astellas Pharma/Iveric Bio
IZERVAY, also known as avacincaptad pegol is designed to target and inhibit complement factor C5. Complement factor C5 is a central component of the complement cascade and is believed to be involved in the development and progression of dry AMD. IZERVAY binds to C5 and inhibits its cleavage into the terminal fragments C5a and C5b. By inhibiting the formation of complement system terminal fragments, IZERVAY may decrease the activation of inflammasomes and the formation of membrane attack complexes (MAC), which occur at the end of the complement cascade. In August 2023, the US FDA approved IZERVAY for the treatment of Geographic Atrophy secondary to AMD. Concurrently, Astellas Pharma announced that the European Medicines Agency (EMA) has accepted Iveric Bio's MAA for avacincaptad pegol for the treatment of Geographic Atrophy secondary to AMD.
* SYFOVRE (pegcetacoplan): Apellis Pharmaceuticals
SYFOVRE is a targeted C3 inhibitor designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is a type of synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b. The company is evaluating pegcetacoplan in several clinical studies, including paroxysmal nocturnal hemoglobinuria (PNH), Geographic Atrophy (GA), cold agglutinin disease (CAD), warm antibody autoimmune hemolytic anemia (wAIHA), complement-dependent nephropathies (CDN). SYFOVRE is the first and only approved therapy for Geographic Atrophy secondary to AMD. In January 2024, the CHMP of the EMA adopted a negative opinion on the MAA of intravitreal pegcetacoplan for the treatment of Geographic Atrophy secondary to AMD.
Emerging Geographic Atrophy Drugs
* Tinlarebant (LBS-008): Belite Bio
Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to GA, or advanced dry AMD. These toxins are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. A 2-year global Phase III PHOENIX trial is ongoing. PHOENIX is a multicenter, randomized, double-masked, placebo-controlled study to evaluate the safety and efficacy of Tinlarebant in Geographic Atrophy subjects. In November 2023, Belite Bio announced the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom (UK) for the Phase III clinical trial of Tinlarebant in Geographic Atrophy or the PHOENIX study.
* Gildeuretinol (ALK-001): Alkeus Pharmaceuticals
Allegro Ophthalmics is developing risuteganib (also known as ALG-1001), a breakthrough integrin-regulating therapy for ocular health that reduces mitochondrial dysfunction involved in intermediate dry AMD. By targeting multiple pathways, risuteganib helps reduce the cellular burden of oxidative stress and restores retinal homeostasis. Research suggests that risuteganib interferes with integrin functions that have been implicated in retinal diseases, giving it the potential for a broad-spectrum effect on different pathways of oxidative stress. Currently, the company has received the US FDA agreement under Special Protocol Assessment (SPA) for Phase IIb/III clinical trial of risuteganib for the treatment of intermediate, non-exudative age-related macular degeneration (dry AMD). Moreover, the overall protocol design of Phase IIb/III dry AMD clinical trial was finalized by the US FDA. According to the company's recent presentation, a Phase III study of gildeuretinol in 200 patients with Geographic Atrophy secondary to AMD has recently been completed and is expected to read out topline data in 2024.
Geographic Atrophy Market Outlook
Geographic Atrophy, the advanced stage of dry AMD, has emerged as a prominent focus of research. Current investigations predominantly center on therapies targeting complement inhibitors of C3 and C5, pivotal factors in triggering inflammation and subsequent cell death within the eye. Extensive studies led by the National Eye Institute and esteemed researchers globally have unveiled the likelihood of an overactive complement system as a central player in the genesis of dry AMD and its evolution toward Geographic Atrophy.
To know more about Geographic Atrophy treatment guidelines, visit @ Geographic Atrophy Treatment Market Landscape [https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Geographic Atrophy Drugs Uptake
* IZERVAY , developed by Astellas Pharma/Iveric Bio is designed to target and inhibit complement factor C5. IZERVAY binds to C5 and inhibits its cleavage into the terminal fragments C5a and C5b. In August 2023, the US FDA approved IZERVAY for the treatment of geographic atrophy secondary to AMD.
* SYFOVRE , developed by Apellis Pharmaceuticals is a targeted C3 inhibitor designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is a type of synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b. In February 2023, the US FDA approved SYFOVRE for the treatment of geographic atrophy secondary to AMD.
Geographic Atrophy Market Dynamics
The Geographic Atrophy market dynamics are expected to change in the coming years. Payers' willingness to pay is assumed to be strong since the unavailability of approved medicines creates a high unmet demand and the possibility of avoiding progression to wet AMD, which is associated with high treatment costs. Moreover, due to the existing absence of competitive therapies, clinical outcome requirements may be minimal; hence, sham or placebo-controlled clinical trials may suffice for initial entrants. Furthermore, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the geographic atrophy market in the 7MM.
Major Geographic Atrophy Companies
Aviceda Therapeutics, Iveric Bio, Alkeus Pharmaceuticals, Allegro Ophthalmics, Stealth BioTherapeutics, Novartis, Perceive Biotherapeutics, Inc., Genentech, Inc., NGM Biopharmaceuticals, Inc, Annexon, Inc., Regenerative Patch Technologies, LLC, Apellis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Astellas Pharma Inc, Gyroscope Therapeutics Limited, and others.
Learn more about the FDA-approved drugs for Geographic Atrophy @ Drugs for Geographic Atrophy Treatment [https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Geographic Atrophy Market Report
* Coverage- 7MM
* Geographic Atrophy Companies- Aviceda Therapeutics, Iveric Bio, Alkeus Pharmaceuticals, Allegro Ophthalmics, Stealth BioTherapeutics, Novartis, Perceive Biotherapeutics, Inc., Genentech, Inc., NGM Biopharmaceuticals, Inc, Annexon, Inc., Regenerative Patch Technologies, LLC, Apellis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Astellas Pharma Inc, Gyroscope Therapeutics Limited, and others.
* Geographic Atrophy Therapies- AVD-104, Zimura (avacincaptad pegol), ALK-001, Risuteganib, Elamipretide, PPY988, VOY-101, OpRegen, NGM621, ANX007, CPCB-RPE1, APL-2, IONIS-FB-LRx, ASP7317, GT005, and others.
* Geographic Atrophy Market Dynamics: Geographic Atrophy Market Drivers and Barriers
* Geographic Atrophy Market Access and Reimbursement, Unmet Needs and Future Perspectives
Table of Content
1. Key Insights
2. Geographic Atrophy Executive Summary
3. Competitive Intelligence Analysis for Geographic Atrophy
4. Geographic Atrophy: Market Overview at a Glance
5. Geographic Atrophy: Disease Background and Overview
6. Geographic Atrophy Patient Journey
7. Geographic Atrophy Epidemiology and Patient Population
8. Geographic Atrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Geographic Atrophy Unmet Needs
10. Key Endpoints of Geographic Atrophy Treatment
11. Geographic Atrophy Marketed Products
12. Geographic Atrophy Emerging Therapies
13. Geographic Atrophy: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Geographic Atrophy Market Outlook
16. Geographic Atrophy Market Access and Reimbursement Overview
17. Geographic Atrophy KOL Views
18. Geographic Atrophy Market Drivers
19. Geographic Atrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=geographic-atrophy-therapeutics-market-size-in-the-7mm-is-expected-to-grow-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Geographic Atrophy Therapeutics Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight here
News-ID: 3787578 • Views: …
More Releases from ABNewswire

Cheapest Detroit Pistons vs. Rivals Tickets at Little Caesars Arena - CITY10 Pro …
Get the cheapest Detroit Pistons tickets for games against top rivals at Little Caesars Arena! Use promo code CITY10 at CapitalCityTickets.com to unlock exclusive discounts. Compare seating options, secure your spot courtside, and enjoy live NBA action without overspending. Don't miss thrilling Pistons matchups-grab your discounted tickets today and experience the excitement of every game!
The 2025-26 NBA season is here, and the Detroit Pistons are ready to ignite Little Caesars…

Precision in Healthcare Communication: Why ITA Members Are the Right Choice for …
Medical translation requires absolute accuracy, specialized knowledge, and sensitivity to cultural and linguistic differences. Members of the Israel Translators Association (ITA) bring expertise in medicine, pharmaceuticals, and healthcare, ensuring that clinical trials, patient records, and medical device manuals are translated with precision and confidentiality. Choosing an ITA member guarantees professional standards and dependable results in this critical field
In medicine, words can save lives-or put them at risk. Accurate communication is…

Best Deals on 2025 Milwaukee Bucks NBA Tickets - Use Promo CITY10 Online at Capi …
Get the best deals on 2025 Milwaukee Bucks tickets at CapitalCityTickets.com! Choose from a wide selection of seat levels and enjoy even greater savings by applying promo code CITY10 at checkout. Secure your tickets now and cheer on the Bucks live at Fiserv Forum or on the road-while seats last!
Looking for the best deals on Milwaukee Bucks NBA tickets for the 2025-26 season? You can score affordable tickets to see…

Affordable Montreal Canadiens Bell Centre Tickets Online - Save with Promo Code …
Score affordable Montreal Canadiens tickets at Bell Centre! Use promo code CITY10 at CapitalCityTickets.com to save on your seats. Compare ticket options, find the best views, and secure your spot to watch the Canadiens live. Don't miss top NHL action-grab discounted tickets today and enjoy thrilling hockey games without overspending!
As the 2025-26 NHL season ignites, the Montreal Canadiens are gearing up to light up the Bell Centre with their signature…
More Releases for Geographic
Geographic Information System (GIS) Software Global Market Report 2024 - Geograp …
"The Business Research Company recently released a comprehensive report on the Global Geographic Information System (GIS) Software Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The…
Cybersecurity Market Regional Analysis | Evaluating Geographic Trends
Cybersecurity Market Scope and Overview
In the digital era, where information is the new currency, cybersecurity emerges as a paramount concern for individuals, businesses, and governments alike. With the exponential growth of cyber threats, the global Cybersecurity Market has witnessed a surge in demand for innovative solutions and services to safeguard sensitive data and critical infrastructure. This report delves into a comprehensive analysis of the cybersecurity market, covering key players, market…
Geographic Information System - Comprehensive Analysis
GIS is used to power millions of decisions every day all over the world, such as examining crime patterns, pinpointing novel store locations, directing in-car navigation, and predicting and forecasting the weather, among others. The growing demand for location-based analytics among businesses to enhance operational efficiency and improve decision-making is driving the market growth. Similarly, the necessity to combine traditional data with three-dimensional data to get valuable insights from location-based…
Automobile Accessories Market: Charting New Geographic Territory
An extensive analysis of the Automobile Accessories market strategy of the leading companies in the precision of import/export consumption, supply and demand figures, cost, price, revenue and gross margins. The report starts by an introduction about the company profiling and a comprehensive review about the strategy concept and the tools that can be used to assess and analyze strategy. It also analyzes the company’s strategy in the light of Porter’s…
Geographic Atrophy - Pipeline Review, H2 2018 - ResearchByMarkets.com
"Geographic Atrophy - Pipeline Review, H2 2018", provides an overview of the Geographic Atrophy (Ophthalmology) pipeline landscape.
Geographic atrophy is an advanced form of age-related macular degeneration that can result in the progressive and irreversible loss of retina which can lead to a loss of visual function over time. Symptoms include difficulty during reading. Risk factors include smoking, thyroid hormones or antacids and in patients with coronary heart diseases and cataract…
MapsOfWorld.com partners with National Geographic Maps
MapsOfWorld.com has proudly partnered with National Geographic Maps to sell National Geographic maps and atlases in the United States. All wall maps are available at an initial discount of 15%, along with additional discounts on bulk items ordered by corporations and schools. Range of products available for sale include: paper and laminated wall maps, mural (wall paper) maps, travel maps and atlases. Wall maps are available in National Geographic’s three…